Oncolys president reflects on journey to world-first cancer treatment

Kiswahili

Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.

The treatment is described as a world-first viral therapy. Urata expressed hope that it will improve quality of life for patients with esophageal cancer.

The approval marks the culmination of extended efforts by the pharmaceutical company based in Japan. Details of the therapy's mechanism were not specified in available reports.

The Japan Times published the account on June 18, 2026.

Makala yanayohusiana

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
Picha iliyoundwa na AI

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

Bioinvent hosts kol event on ovarian cancer therapies

Imeripotiwa na AI

BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.

Health

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Europe

CRIS Cancer to donate 3.6 million to Vega Oncotargets after controversy

Health

AI identifies breast cancer drug for multiple viruses

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

Jumanne, 9. Mwezi wa sita 2026, 17:25:16

Longevity startup doses first patient in vision loss trial

Ijumaa, 29. Mwezi wa tano 2026, 15:41:51

Virus injection halts pancreatic tumor growth in trial

Jumapili, 17. Mwezi wa tano 2026, 08:37:15

Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Jumamosi, 16. Mwezi wa tano 2026, 00:33:35

Caribou Biosciences presents car-t updates at healthcare conference

Jumapili, 29. Mwezi wa tatu 2026, 08:38:05

CK Life unit Sequencio eyes China fast track for cancer vaccines

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa